Biodesix (BDSX) Non-Current Debt (2019 - 2026)

Biodesix has reported Non-Current Debt for 8 years, with the latest figure at $46.5 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt rose 26.69% year-over-year to $46.5 million; the trailing twelve-month figure through Mar 2026 stood at $46.5 million (up 26.69% YoY), and the FY2025 full-year result was $47.4 million, up 30.31% from the prior year.
• Non-Current Debt for Q1 2026 stood at $46.5 million, down from $47.4 million in the prior quarter.
• The five-year high for Non-Current Debt was $47.4 million in Q4 2025, with the low at $4.9 million in Q3 2022.
• Historically, Non-Current Debt has averaged $31.0 million across 5 years, with a median of $35.5 million in 2024.
• Annual changes were most pronounced in 2022 — Non-Current Debt plunged 83.72% — and 2023, when it jumped 411.27%.
• Biodesix's Non-Current Debt stood at $25.0 million in 2022, then jumped by 40.88% to $35.2 million in 2023, then increased by 3.36% to $36.4 million in 2024, then soared by 30.31% to $47.4 million in 2025, then retreated by 2.02% to $46.5 million in 2026.
• The last three Non-Current Debt figures came in at $46.5 million (Q1 2026), $47.4 million (Q4 2025), and $47.1 million (Q3 2025), per Business Quant data.